New injection GenSci120 takes first step toward taming autoimmune disease

NCT ID NCT06827457

Completed Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a single injection of GenSci120 in 58 healthy adults to see if it is safe and how the body processes it. The drug aims to control the immune system, which could one day help people with autoimmune diseases. Because this is a Phase 1 study, it only looks at safety and dosing, not yet whether it works for any specific condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GenSci120
What this could lead to: If successful, this could lead to a new treatment option for autoimmune diseases by controlling the immune system.
What could go wrong: This is a very early Phase 1 trial in only 58 healthy people, so it cannot yet show if the drug works for any disease. Safety and dosing are the only goals here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASE

Contacts and locations

Locations

Huashan Hospital

Shanghai, Shanghai Municipality, 20040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.